SciSparc Closes Sale of MitoCareX to N2OFF

Reuters10-24

SciSparc Closes Sale of MitoCareX to N2OFF

SciSparc Ltd. has completed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. Under the terms of the agreement, N2OFF acquired 6,622 shares of MitoCareX from SciSparc for $700,000 and exchanged the remaining outstanding shares of MitoCareX with all sellers for shares of N2OFF's common stock, representing 40% of N2OFF's fully diluted capital stock. The sellers will also be entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years following the closing date. Following the transaction, MitoCareX is now a wholly owned subsidiary of N2OFF, with its board reconstituted by N2OFF appointees. The agreement also includes milestone-based issuances of up to 25% of N2OFF's common stock, calculated on a fully diluted basis, to the sellers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550998-en) on October 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577535877?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 04:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577535877","market":"us","top_or_hot":-1,"title":"SciSparc Closes Sale of MitoCareX to N2OFF","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SciSparc Closes Sale of MitoCareX to N2OFF\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRC\">SciSparc Ltd.</a> has completed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to <a href=\"https://laohu8.com/S/NITO\">N2OFF, Inc</a>. Under the terms of the agreement, N2OFF acquired 6,622 shares of MitoCareX from SciSparc for $700,000 and exchanged the remaining outstanding shares of MitoCareX with all sellers for shares of N2OFF's common stock, representing 40% of N2OFF's fully diluted capital stock. The sellers will also be entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years following the closing date. Following the transaction, MitoCareX is now a wholly owned subsidiary of N2OFF, with its board reconstituted by N2OFF appointees. The agreement also includes milestone-based issuances of up to 25% of N2OFF's common stock, calculated on a fully diluted basis, to the sellers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550998-en) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SciSparc Closes Sale of MitoCareX to N2OFF</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSciSparc Closes Sale of MitoCareX to N2OFF\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 04:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SciSparc Closes Sale of MitoCareX to N2OFF\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRC\">SciSparc Ltd.</a> has completed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to <a href=\"https://laohu8.com/S/NITO\">N2OFF, Inc</a>. Under the terms of the agreement, N2OFF acquired 6,622 shares of MitoCareX from SciSparc for $700,000 and exchanged the remaining outstanding shares of MitoCareX with all sellers for shares of N2OFF's common stock, representing 40% of N2OFF's fully diluted capital stock. The sellers will also be entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years following the closing date. Following the transaction, MitoCareX is now a wholly owned subsidiary of N2OFF, with its board reconstituted by N2OFF appointees. The agreement also includes milestone-based issuances of up to 25% of N2OFF's common stock, calculated on a fully diluted basis, to the sellers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550998-en) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRC","symbol_name":"SciSparc Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL8vzwxp:1","article_id":"2577535877","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577535877","pubTimestamp":1761249790,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SciSparc Ltd. has completed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. Under the terms of the agreement, N2OFF acquired 6,622 shares of MitoCareX from SciSparc for $700,000 and exchanged the remaining outstanding shares of MitoCareX with all sellers for shares of N2OFF's common stock, representing 40% of N2OFF's fully diluted capital stock. The sellers will also be entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years following the closing date. Following the transaction, MitoCareX is now a wholly owned subsidiary of N2OFF, with its board reconstituted by N2OFF appointees. The agreement also includes milestone-based issuances of up to 25% of N2OFF's common stock, calculated on a fully diluted basis, to the sellers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPRC":"SciSparc Ltd.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","BK4007":"制药","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4093":"化肥与农用药剂","BK4588":"碎股","BK4539":"次新股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NITO":"N2OFF, Inc","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"SciSparc完成向N2OFF出售MitoCareX","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRC":0.9,"NITO":0.9,"NDAQ":0.9},"content_text":"SciSparc Closes Sale of MitoCareX to N2OFF\n    \n\nSciSparc Ltd. has completed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. Under the terms of the agreement, N2OFF acquired 6,622 shares of MitoCareX from SciSparc for $700,000 and exchanged the remaining outstanding shares of MitoCareX with all sellers for shares of N2OFF's common stock, representing 40% of N2OFF's fully diluted capital stock. The sellers will also be entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years following the closing date. Following the transaction, MitoCareX is now a wholly owned subsidiary of N2OFF, with its board reconstituted by N2OFF appointees. The agreement also includes milestone-based issuances of up to 25% of N2OFF's common stock, calculated on a fully diluted basis, to the sellers.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550998-en) on October 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577535877","isCrawlerRequest":true}